Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of PARP inhibition combined with EZH2 inhibition depends on BRCA mutation status and microenvironment in breast cancer.

The FEBS journal - 1 May 2021

Chen Mei-Kuang

Abstract excerpt

The efficacy of the combination of a PARP inhibitor (PARPi) and an EZH2 inhibitor has been investigated in breast cancer cells with either BRCA1 mutation or BRCA2 mutation. However, earlier studies focused on the efficacy of this combination against BRCA-mutated but not BRCA-proficient breast cancer. Yang et al. observed that PARP1 depletion combined with EZH2 depletion via PRC2 depletion did not affect the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Enhancer of Zeste Homolog 2 Protein

Share to Mutation

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 33570247
DOI: 10.1111/febs.15730
PMCID: PMC8096666

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Efficacy of PARP inhibition combined with EZH2 inhibition depends on BRCA mutation status and microenvironment in breast cancer.PMID 33570247Read ↗

Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challengesSemantic proximity Read ↗

RBR-type E3 ubiquitin ligase RNF144A targets PARP1 for ubiquitin-dependent degradation and regulates PARP inhibitor sensitivity in breast cancer cellsSemantic proximity Read ↗

Emerging Combination Strategy: FANCI Inhibition Induces PARP1 Redistribution to Enhance Efficacy of PARP Inhibitors in Breast CancerSemantic proximity Read ↗

HER2 Overexpression Renders Human Breast Cancers Sensitive to PARP Inhibition Independently of Any Defect in Homologous Recombination DNA RepairSemantic proximity Read ↗

Therapeutic advances and application of PARP inhibitors in breast cancerSemantic proximity Read ↗

The potential of PARP inhibitors in targeted cancer therapy and immunotherapySemantic proximity Read ↗

PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor ResistanceSemantic proximity Read ↗

An overview of the research progress of BRCA gene mutations in breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.